Endologix to Report Fourth Quarter and Full Year 2009 Financial Results on February 18, 2010

Friday, February 12, 2010 Corporate News J E 4

IRVINE, Calif., Feb. 11 Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2009 financial results, which will take place on Thursday, February 18, 2010 after the close of the market.

Endologix will hold a conference call on Thursday, February 18, 2010 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate website at

After the live Web cast, the call will remain available on Endologix's Web site,, through March 18, 2010. In addition, a telephonic replay of the call will be available until February 25, 2010. The replay dial-in numbers are (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. Please use account number 3055 and conference ID number 343302.

About Endologix

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at

COMPANY CONTACT: INVESTOR CONTACTS: ---------------- ------------------ Endologix, Inc. The Ruth Group John McDermott, CEO Nick Laudico (646) 536-7030 (949) 595-7200 Zack Kubow (646) 536-7020

SOURCE Endologix, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Patient Access Network Opens 5 New Funds Including...
Morningstar and NYSSA to Host Healthcare Conferenc...